文献速递乳腺癌

加速表柔比星对比标准表柔比星后序贯环磷酰胺、甲氨蝶呤和氟尿嘧啶或卡培他滨辅助治疗乳腺癌(UK TACT2;CRUK/05/19):多中心、3期、开放标签、随机对照试验的生活质量结果

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
PubMed 文献 · Lancet Oncol · 2023-11-02

UK TACT2试验纳入4391例早期乳腺癌患者,其中1281例参与生活质量亚研究。加速表柔比星仅在治疗期间生活质量差于标准表柔比星;CMF的生活质量影响差于卡培他滨且持续至24个月。

要点

  • 加速表柔比星较标准表柔比星在治疗期间身体功能、角色功能、疲乏及全身副作用更差,但未持续。
  • CMF较卡培他滨在治疗结束时抑郁评分及HADS总分变化更差。
  • CMF较卡培他滨的身体功能、性功能、疲乏及全身副作用更差,持续至12和24个月。

核心结论

  • 加速表柔比星仅在治疗期间与较标准表柔比星更差的生活质量相关。
  • CMF较卡培他滨的生活质量影响更差,且持续24个月。
  • 卡培他滨较CMF更有利的生活质量支持其作为三阴性乳腺癌新辅助化疗后的辅助选择。

研究设计与样本

  • TACT2为多中心、3期、开放标签、平行组、随机对照试验,在129个英国中心进行。
  • 参与者为18岁及以上、组织学确诊的淋巴结阳性或高危淋巴结阴性侵袭性原发性乳腺癌、已完整切除并计划接受辅助化疗的患者。
  • 患者按1:1:1:1随机分配至四周期100 mg/m2表柔比星每3周一次(标准表柔比星)或每2周一次联合每周期第2天6 mg培非格司亭(加速表柔比星),随后序贯四周期4周方案的CMF或四周期3周方案的卡培他滨2500 mg/m2。
  • 生活质量亚研究纳入44个中心中1493例合格患者中的1281例(85·8%)。

主要发现

  • 治疗结束时HADS抑郁评分(p=0·0048)和HADS总分变化(p=0·0093)CMF较卡培他滨更差。
  • 治疗期间加速表柔比星较标准表柔比星身体功能(p=0·0065)、角色功能(p<0·0001)、疲乏(p=0·0002)和全身副作用(p=0·0001)更差,性功能(p=0·36)无显著差异,但该效应未持续。
  • 治疗结束时CMF较卡培他滨身体功能(p=0·0048)、性功能(p=0·0053)、疲乏(p<0·0001)和全身副作用(p<0·0001)更差,角色功能(p=0·013)无显著差异;这些差异在12个月和24个月持续存在。

临床怎么用

  • 原文结论指出,这些发现将帮助患者和临床医生对加速化疗做出知情选择。
  • 作者认为,卡培他滨较CMF更有利的生活质量支持其作为三阴性乳腺癌患者新辅助化疗后的辅助选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant chemotherapy for patients with early breast cancer improves outcomes but its toxicity affects patients' quality of life (QOL). The UK TACT2 trial investigated whether accelerated epirubicin improves time to recurrence and if oral capecitabine is non-inferior to cyclophosphamide, methotrexate, and fluorouracil (CMF) for efficacy with less toxicity. Results showed no benefit for accelerated epirubicin and capecitabine was non-inferior. As part of the QOL substudy, we aimed to assess the effect of chemotherapies on psychological distress, physical symptoms, and functional domains. METHODS: TACT2 was a multicentre, phase 3, open-label, parallel-group, randomised, controlled trial done in 129 UK centres. Participants were aged 18 years or older with histologically confirmed node-positive or high-risk node-negative invasive primary breast cancer, who had undergone complete excision, and due to receive adjuvant chemotherapy. Patients were randomly assigned (1:1:1:1) to four cycles of 100 mg/m2 epirubicin either every 3 weeks (standard epirubicin) or every 2 weeks with 6 mg pegfilgrastim on day 2 of each cycle (accelerated epirubicin), followed by four 4-week cycles of either CMF (600 mg/m2 cyclophosphamide intravenously on days 1 and 8 or 100 mg/m2 orally on days 1-14; 40 mg/m2 methotrexate intravenously on days 1 and 8; and 600 mg/m2 fluorouracil intravenously on days 1 and 8 of each cycle) or four 3-week cycles of 2500 mg/m2 capecitabine (1250 mg/m2 given twice daily on days 1-14 of each cycle). The randomisation schedule was computer generated in random permuted blocks, stratified by centre, number of nodes involved (none vs 1-3 vs ≥4), age (≤50 years vs >50 years), and planned endocrine treatment (yes vs no). QOL was one of the secondary outcomes and is reported here. All patients from a subset of 44 centres were invited to complete QOL questionnaires (Hospital Anxiety and Depression Scale [HADS] and European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire 30-item core module [QLQ-C30] and Quality of Life Questionnaire breast module [QLQ-BR23]) at baseline, end of standard or accelerated epirubicin, end of CMF or capecitabine, and at 12 and 24 months after randomisation. The QOL substudy prespecified two coprimary QOL outcomes assessed in the intention-to-treat population: overall QOL (reported elsewhere) and HADS total score. Prespecified secondary QOL outcomes were EORTC QLQ-C30 subscales of physical function, role function, and fatigue and EORTC QLQ-BR23 subscales of sexual function and systemic therapy side-effects. This trial is registered with ISRCTN, ISRCTN68068041, and ClinicalTrials.gov, NCT00301925. FINDINGS: From Dec 16, 2005, to Dec 5, 2008, 4391 patients (20 [0·5%] of whom were male) were enrolled in TACT2; 1281 (85·8%) of 1493 eligible patients were included in the QOL substudy. Eight (0·6%) participants in the QOL substudy were male and 1273 (99·4%) were female. Median follow-up was 85·6 months (IQR 80·6-95·9). Analysis was performed on the complete QOL dataset (as of Sept 15, 2011) when all participants had passed the 24-month timepoint. Prerandomisation questionnaires were completed by 1172 (91·5%) patients and 1179 (92·0%) completed at least one postrandomisation questionnaire. End-of-treatment HADS depression score (p=0·0048) and HADS total change score (p=0·0093) were worse for CMF versus capecitabine. Accelerated epirubicin led to worse physical function (p=0·0065), role function (p<0·0001), fatigue (p=0·0002), and systemic side-effects (p=0·0001), but not sexual function (p=0·36), compared with standard epirubicin during treatment, but the effect did not persist. Worse physical function (p=0·0048), sexual function (p=0·0053), fatigue (p<0·0001), and systemic side-effects (p<0·0001), but not role functioning (p=0·013), were seen for CMF versus capecitabine at end of treatment; these differences persisted at 12 months and 24 months. INTERPRETATION: Accelerated epirubicin was associated with worse QOL than was standard epirubicin but only during treatment. These findings will help patients and clinicians make an informed choice about accelerated chemotherapy. CMF had worse QOL effects than did capecitabine, which were persistent for 24 months. The favourable capecitabine QOL compared with CMF supports its use as an adjuvant option after neoadjuvant chemotherapy in patients with triple-negative breast cancer. FUNDING: Cancer Research UK, Amgen, Pfizer, and Roche.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Velikova G, Morden JP, Haviland JS, et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2023. PMID: 37926100. doi:10.1016/S1470-2045(23)00460-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。